BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

OncoGenex Pharmaceuticals Inc. 

1522 217th Place SE
Suite 100
Bothell  Washington  98021  U.S.A.
Phone: 425-686-1500 Fax: 425-686-1600


SEARCH JOBS



OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.

We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.

We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.

In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:

• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer;
• a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and
• a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.

We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.

Learn more about OncoGenex at www.oncogenex.com

US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500

Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678



 Key Statistics


Email:
Ownership:

Web Site: OncoGenex Pharmaceuticals Inc.
Employees:
Symbol: OGXI
 









 Company News
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer 9/16/2014 8:10:45 AM
Update: OncoGenex Pharmaceuticals Inc. (OGXI) Phase 3 ENSPIRIT Trial Continuing As Planned 8/22/2014 6:05:19 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2014 8/8/2014 7:48:52 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2014 8/7/2014 2:16:41 PM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Appointment Of John A. Bencich As Vice President And Chief Financial Officer 8/7/2014 8:23:16 AM
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Second Quarter 2014 On August 7, 2014 7/24/2014 10:23:03 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Cedar™ Clinical Trial Evaluating Apatorsen In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer Is Now Open For Enrollment 7/1/2014 8:20:38 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Pricing Of $24 Million Underwritten Registered Direct Offering 6/27/2014 8:37:50 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Retrenches, And Searches For Answers, After Failed Trial 5/22/2014 7:45:55 AM
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For First Quarter 2014 5/1/2014 7:33:54 AM
12345678910...